M. Williams

发表

Defining the role of pharmacology in the emerging world of translational research.

S. Enna, M. Williams, Michael Williams, 2009, Advances in pharmacology.

Challenges in the Search for Drugs to Treat Central Nervous System Disorders

M. Williams, Michael Williams, M Williams, 2009, Journal of Pharmacology and Experimental Therapeutics.

Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data.

M. Williams, W. J. Giardina, Michael Williams, 2006, CNS drug reviews.

Organizing for drug discovery.

M. Williams, Michael Williams, G. Neil, 1988, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, Y. Martin, S. Arneric, 1996, Journal of medicinal chemistry.

Effects of Purine Nucleotides on the Binding of [3H]Cyclopentyladenosine to Adenosine A‐l Receptors in Rat Brain Membranes

M. Williams, A. Braunwalder, 1986, Journal of neurochemistry.

Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface

P. Mcgonigle, M. Williams, 2014 .

Neuronal nicotinic acetylcholine receptors as novel drug targets.

M. Williams, G. Lloyd, Lloyd Gk, 2000, The Journal of pharmacology and experimental therapeutics.

Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics.

J. Sullivan, J. Daly, M. Decker, 2000, Natural product reports.

Fifty years of Biochemical Pharmacology: the discipline and the journal.

J. Piette, G. Feuerstein, S. Enna, 2008, Biochemical pharmacology.

Potent dopamine agonist activity of a novel ergoline, 6-ethyl-9-oxaergoline (EOE).

M. Williams, J. Jones, G. Yarbrough, 1982, Life sciences.

Agonist derived molecular probes for A2 adenosine receptors

L. Pannell, K. Jacobson, G. Stiles, 1989, Journal of molecular recognition : JMR.

Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking.

K. Jacobson, G. Stiles, M. Williams, 1989, Proceedings of the National Academy of Sciences of the United States of America.

A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.

M. Williams, G. Martin, D. Haubrich, 1982, The Journal of pharmacology and experimental therapeutics.

Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities.

S. Arneric, J. Sullivan, D. Garvey, 1994, Journal of medicinal chemistry.

P2 purinergic receptors: modulation of cell function and therapeutic potential.

G. Burnstock, M. Williams, Michael Williams, 2000, The Journal of pharmacology and experimental therapeutics.

Adenosine is an Antiinflammatory Autocoid: Adenosine Receptor Occupancy Promotes Neutrophil Chemotaxis and Inhibits Superoxide Anion Generation

B. Cronstein, D. Nicholls, M. Williams, 1990 .

Characterization of Adenosine Receptors in the PC 12 Pheochromocytoma Cell Line Using Radioligand Binding: Evidence for A‐2 Selectivity

M. Williams, M. Jarvis, M. Abreu, 1987, Journal of neurochemistry.

Biochemical characterization of the antagonist actions of the xanthines, PACPX (1,3-dipropyl-8(2-amino-4-chloro)phenylxanthine) and 8-PT (8-phenyltheophylline) at adenosine A1 and A2 receptors in rat brain tissue.

M. Williams, M. Jarvis, J. Ferkany, 1987, Biochemical pharmacology.

Interaction of avermectins with [3H]beta-carboline-3-carboxylate ethyl ester and [3H]diazepam binding sites in rat brain cortical membranes.

M. Williams, E. Risley, 1982, European journal of pharmacology.

Purines: from premise to promise.

M. Williams, 2000, Journal of the autonomic nervous system.

Enhancement of the binding of 3H-diazepam to rat brain membranes in vitro by SQ 20009, A novel anxiolytic, gamma-aminobutyric acid (GABA) and muscimol.

M. Williams, E. Risley, Michael Williams, 1979, Life sciences.

Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome.

M. Williams, S. Bischoff, M. Heinrich, 1988, Journal of receptor research.

Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist.

G. Ghai, M. Williams, M. B. Zimmerman, 1987, The Journal of pharmacology and experimental therapeutics.

Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex.

M. Williams, M. Jarvis, M. Sills, 1991, Molecular pharmacology.

The novel anticonvulsant MK-801 interacts with central phencyclidine recognition sites in rat brain.

M. Williams, P. Loo, A. Braunwalder, 1987, European Journal of Pharmacology.

Central phencyclidine (PCP) receptor binding is glutamate dependent: evidence for a PCP/excitatory amino acid receptor (EAAR) complex

M. Williams, J. Lehmann, P. Loo, 1986 .

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.

S. Arneric, M. Decker, N. Lin, 1998, The Journal of pharmacology and experimental therapeutics.

Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, R. Porsolt, S. Arneric, 1998, Science.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1998, The Journal of pharmacology and experimental therapeutics.

Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist.

M. Williams, Y. Girard, G. Yarbrough, 1982, Journal of medicinal chemistry.

Binding of the nicotinic cholinergic antagonist, dihydro-beta- erythroidine, to rat brain tissue

M. Williams, J. L. Robinson, 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rat brain: evidence for multiple affinity states of the phencyclidine/N-methyl-D-aspartate receptor complex.

M. Williams, J. Lehmann, P. Loo, 1987, Molecular pharmacology.

Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists.

M. Williams, J. Lehmann, P. Loo, 1986, European journal of pharmacology.

4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity.

M. Williams, D. Murphy, P. Bernard, 1989, Journal of medicinal chemistry.

Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

M. Williams, P. van Galen, K A Jacobson, 1992, Journal of medicinal chemistry.

2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.

G. Ghai, M. Williams, M. Jarvis, 1990, Journal of medicinal chemistry.

Synthesis, opioid receptor binding profile, and antinociceptive activity of 1-azaspiro[4.5]decan-10-yl amides.

M. Williams, R. Fujimoto, J. Simke, 1989, Journal of medicinal chemistry.

Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..

M. Williams, S. Bhagwat, M. Jarvis, 2001, Journal of medicinal chemistry.

Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis.

G. Firestein, D. Boyle, M. Williams, 2001, The Journal of pharmacology and experimental therapeutics.

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.

J. Kebabian, P. Jenner, M. Williams, 1992, European journal of pharmacology.

Purinergic and pyrimidinergic receptors as potential drug targets.

M. Williams, M. Jarvis, M Williams, 2000, Biochemical pharmacology.

Nomenclature and Classification of Purinoceptors*

G Burnstock, B B Fredholm, B. Fredholm, 2005 .

[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.

M. Williams, M. Jarvis, M. Sills, 1989, The Journal of pharmacology and experimental therapeutics.

Purine receptors in mammalian tissues: pharmacology and functional significance.

M. Williams, 1987, Annual review of pharmacology and toxicology.

Biochemical characterization of putative central purinergic receptors by using 2-chloro[3H]adenosine, a stable analog of adenosine.

M. Williams, E. Risley, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Towards a revised nomenclature for P1 and P2 receptors.

G Burnstock, B B Fredholm, B. Fredholm, 1997, Trends in pharmacological sciences.

Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680.

M. Williams, M. Jarvis, Michael Williams, 1989, European journal of pharmacology.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, S. Arneric, C. Briggs, 1998, Journal of medicinal chemistry.

Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.

S. Arneric, M. Decker, N. Lin, 1998, European journal of pharmacology.

Enhancement of in vitro binding and some of the pharmacological properties of diazepam by a novel anthelmintic agent, Avermectin B1a.

M. Williams, G. Yarbrough, 1979, European journal of pharmacology.

Antihypertensive beta-adrenergic blocking agents: N-aralkyl analogues of 2-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.

G. F. Lundell, W. Randall, J. Baldwin, 1983, Journal of medicinal chemistry.

Sub-chronic administration of ethanol to mice does not modify the inhibitory effects of dieldrin, abamectin and the dihydropyrazole RH-3421 at their respective sites of action in the nervous system.

R. Nicholson, M. Williams, 1993, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain.

J. Sullivan, D. Anderson, M. Decker, 2000, European journal of pharmacology.

Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.

S. Arneric, J. Sullivan, D. Garvey, 1999, Bioorganic & medicinal chemistry letters.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1997, The Journal of pharmacology and experimental therapeutics.

ABT‐089 [3‐(2(S)‐pyrrolidinylmethoxy)‐2‐methyl‐pyridine]: An orally effective cholinergic channel modulator with potential once‐a‐day dosing and cardiovascular safety

S. Arneric, J. Sullivan, N. Lin, 1997 .

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1997, Journal of medicinal chemistry.

Benzofuro[2,3-c]pyridin-6-ols: synthesis, affinity for opioid-receptor subtypes, and antinociceptive activity.

M. Williams, J. Simke, M. Sills, 1989, Journal of medicinal chemistry.

Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist.

W. Boyar, C. Sinton, M. Williams, 1987, European journal of pharmacology.

Clinical Opportunities in Purinergic Neuromodulation

M. Williams, 2001 .

P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptors

M. Williams, S. Bhagwat, 1997 .

Challenges in developing P2 purinoceptor-based therapeutics.

M. Williams, 2007, Ciba Foundation symposium.

CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist.

C. Sinton, M. Williams, J. Lehmann, 1988, The Journal of pharmacology and experimental therapeutics.

Preparation of some 10-[3-(dimethylamino)-1-propyl]-10H-pyrazino[2,3-b][1,4] benzothiazines as potential neuroleptics.

J. Springer, M. Williams, W. S. Saari, 1983, Journal of medicinal chemistry.

ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.

M. Williams, M. Jarvis, E. Kowaluk, 2000, The Journal of pharmacology and experimental therapeutics.

ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.

A. Gomtsyan, E. Schweitzer, M. Williams, 2000, The Journal of pharmacology and experimental therapeutics.

Novel therapeutics acting via purine receptors.

K. Jacobson, M. Williams, B. K. Trivedi, 1991, Biochemical pharmacology.

Synthesis, assignment of absolute configuration, and receptor binding studies relevant to the neuroleptic activities of a series of chiral 3-substituted cyproheptadine atropisomers.

K. Rittle, P. Anderson, J. Springer, 1979, Journal of medicinal chemistry.

Combination therapy with nucleoside analogs and alkylating agents.

J. Johnston, L. Israels, M. Williams, 1994, Leukemia.

Quantitative autoradiographic localization of NMDA receptors in rat brain using [3H]CPP: comparison with [3H]TCP binding sites.

M. Williams, M. Jarvis, D. Murphy, 1987, European journal of pharmacology.

Selectivity of cyproheptadine as assessed by radioligand binding

M. Williams, G. Martin, 1982, The Journal of pharmacy and pharmacology.

Adenosine Receptors as Drug Targets: Fulfilling the Promise?

M. Williams, 1990 .

Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. II. Effects on macromolecular synthesis in cell culture and evidence for alkylating activity.

R. W. Brockman, M. Williams, R. Struck, 1976, Cancer treatment reports.

Bioactive conformation of 1-arylpiperazines at central serotonin receptors.

J. Springer, J. Huff, M. Williams, 1985, Journal of medicinal chemistry.

Serotonin-releasing effects of substituted piperazines in vitro.

M. Williams, D. Pettibone, Michael Williams, 1984, Biochemical pharmacology.

[3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain.

G. Fagg, M. Williams, M. Pozza, 1991, European journal of pharmacology.

(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).

M. Michaelides, M. Williams, S. Didomenico, 1995, Journal of medicinal chemistry.

The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively.

B. Cronstein, M. Williams, Alan, 1990, The Journal of clinical investigation.

Binding of [3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to rat brain membranes: a selective, high-affinity ligand for N-methyl-D-aspartate receptors.

M. Williams, J. Lehmann, D. Murphy, 1987, The Journal of pharmacology and experimental therapeutics.

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Proceedings of the Western Pharmacology Society.

Alzheimer's disease and related dementias: prospects for treatment.

M. Williams, R. Davis, 1997, Expert opinion on investigational drugs.

The effect of ABT‐702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury

A. Dickenson, M. Williams, M. Jarvis, 2001, British journal of pharmacology.

Purine Nucleosides and Nucleotides as Central Nervous System Modulators

M. Williams, Michael Williams, 1990, Annals of the New York Academy of Sciences.

Stereospecific antidopaminergic and anticholinergic actions of the enantiomers of (+/-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene) piperidine (CTC), a derivative of cyproheptadine.

C. A. Stone, M. Williams, B. Clineschmidt, 1979, The Journal of pharmacology and experimental therapeutics.

Characterization of [3H]ABT-418: a novel cholinergic channel ligand.

S. Arneric, D. Anderson, J. L. Raszkiewicz, 1995, The Journal of pharmacology and experimental therapeutics.

CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.

G. Ghai, M. Williams, M. B. Zimmerman, 1989, The Journal of pharmacology and experimental therapeutics.

2.11 – Enabling Technologies in Drug Discovery: The Technical and Cultural Integration of the New with the Old

M. Williams, M. Williams, 2007 .

Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo.

V. J. Lotti, D. Taylor, M. Williams, 1985, The Journal of pharmacology and experimental therapeutics.

Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].

M. Williams, J. Jones, G. Yarbrough, 1984, The Journal of pharmacology and experimental therapeutics.

Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists.

G. F. Lundell, P. Anderson, J. Hirshfield, 1984, Journal of medicinal chemistry.

Effects of deanol, choline and its metabolites on binding of [3H]quinuclidinyl benzilate to rat brain membranes.

M. Williams, D. Haubrich, E. Risley, 1979, Biochemical pharmacology.

High affinity binding of 2-chloroadenosine to rat brain synaptic membranes.

M. Williams, E. Risley, 1980, European journal of pharmacology.

Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist.

G. Ghai, M. Williams, G. Stone, 1987, The Journal of pharmacology and experimental therapeutics.

Perspectives in Pharmacology Challenges in the Search for Drugs to Treat Central Nervous System Disorders

S. Enna, M. Williams, 2009 .

Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function.

J. Brioni, M. Williams, D. Gauvin, 2001, Life sciences.

Pharmacological characterization of A‐131701, a novel α1‐adrenoceptor antagonist selective for α1A‐ and α1D‐compared to α1B‐adrenoceptors

R. Chess-Williams, M. Williams, C. Chapple, 1998 .

Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.

M. Williams, G. Martin, D. Haubrich, 1981, European journal of pharmacology.

Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes.

M. Williams, J. A. Totaro, 1982, European journal of pharmacology.

Purinergic Neurotransmission: An Historical Background

M. Williams, M. Abbracchio, 2001 .

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

L. Mahan, M. Michaelides, P. Jenner, 1996, The Journal of pharmacology and experimental therapeutics.

RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.

J. P. Long, S. Arneric, D. Goodale, 1983, The Journal of pharmacology and experimental therapeutics.

Assessment of the chloroethyl analog of 3-PPP (N-n-propyl-3-(3-hydroxyphenyl)-piperidine), 3-PPP-C1 as an irreversible ligand for central dopaminergic recognition sites.

M. Williams, J. L. Robinson, K. Watling, 1983, European journal of pharmacology.

Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity.

G. F. Lundell, P. Anderson, J. Hirshfield, 1983, Journal of medicinal chemistry.

Interaction of the putative dopamine autoreceptor agonists, 3-PPP and TL-99, with the dopamine-sensitive adenylate cyclase of carp retina.

M. Williams, K. Watling, 1982, European journal of pharmacology.

Characterization of the binding of [3H]‐CGS 19755: a novel N‐methyl‐d‐aspartate antagonist with nanomolar affinity in rat brain

M. Williams, D. Murphy, S. Hurt, 1988, British journal of pharmacology.

Interaction of 2-phenylaminoadenosine (CV 1808) with adenosine systems in rat tissues.

D. Taylor, M. Williams, 1982, European journal of pharmacology.

Further evidence for selective antagonism of taurine by 6-aminomethyl-3-methyl-4H-1,2,4-benzothiadiazine-1,1-dioxide

M. Williams, G. Martin, R. Bendesky, 1981, Brain Research.

The NMDA antagonists, CPP and CGS 19755, lack affinity for central benzodiazepine receptors.

M. Williams, P. Loo, M. Sills, 1988, European journal of pharmacology.

The novel N‐Methyl‐D‐Aspartate (NMDA) antagonist CGS 19755 prevents ischemia‐induced reductions of adenosine A1, NMDA, and PCP receptors in gerbil brain

M. Williams, M. Jarvis, D. Murphy, 1988, Synapse.

CGS 20625, a novel pyrazolopyridine anxiolytic.

M. Williams, M. Schmutz, D. Wilson, 1989, The Journal of pharmacology and experimental therapeutics.

Interaction of putative anxiolytic agents with central adenosine receptors.

J. Huff, M. Williams, E. Risley, 1981, Canadian journal of physiology and pharmacology.

Inhibition of postsynaptic dopamine-sensitive adenylate cyclase in carp retina by the putative dopamine autoreceptor agonist, 3-PPP.

M. Williams, J. Jones, K. Watling, 1982, European Journal of Pharmacology.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

D. Mckenna, S. Arneric, J. Sullivan, 1996, Neuropharmacology.

The neuropharmacology of a novel gamma-aminobutyric acid analog, kojic amine.

M. Williams, G. Yarbrough, D. Haubrich, 1979, Archives internationales de pharmacodynamie et de therapie.